FDA hands Seat­tle Ge­net­ics its 5th OK for Ad­cetris. But can they ac­tu­al­ly sell it for front­line Hodgkin lym­phoma?

8 years ago
Pharma

GSK launch­es PhI­II lu­pus com­bo study with Benlysta/rit­ux­imab; Ci­pher snatch­es Cana­di­an drug port­fo­lio from Car­diome

8 years ago
News Briefing

Sahm Ad­ran­gi’s Ker­ris­dale knifes Pro­teosta­sis’ 'break­through' cys­tic fi­bro­sis da­ta in a bru­tal biotech short ...

8 years ago
Pharma

As­traZeneca touts a fresh cut of Farx­i­ga da­ta tar­get­ing di­a­betes pa­tients with chron­ic kid­ney dis­ease

8 years ago
R&D

Leapfrog­ging ri­vals, Roche's Tecen­triq plus chemo nabs PFS end­point in front­line lung can­cer seg­ment

8 years ago
R&D

Are­na bounces back. Stock soars on ozan­i­mod ri­val's PhII suc­cess

8 years ago
R&D

Don­ald Trump promis­es (again) to slash drug prices sub­stan­tial­ly; 'and it’s go­ing to be beau­ti­ful’

8 years ago
Pharma

No­vo Nordisk's new obe­si­ty da­ta tip the scales in semaglu­tide's fa­vor as land­mark piv­otal pro­gram looms

8 years ago
R&D

Ho­mol­o­gy, Unum set IPO terms; Knight pays Arde­lyx $19M for tena­panor rights in Cana­da

8 years ago
News Briefing

Trendy an­ti-ag­ing biotech Uni­ty adds $55M as it preps first hu­man tri­al to flush senes­cent cells

8 years ago
Financing

Cidara touts 'pos­i­tive' PhII tri­al da­ta for an­ti­fun­gal, shares yo-yo on the news

8 years ago
R&D

De­nali launch­es a clin­i­cal quest on Alzheimer’s drug, bank­ing $155M in Take­da cash and scor­ing mon­key da­ta on BACE

8 years ago
R&D

Heron's pain drug nails PhI­II, prep­ping the com­pa­ny for NDA lat­er this year

8 years ago
R&D

With No­var­tis and Roche gun­ning to carve up Eylea fran­chise, Re­gen­eron has an­oth­er PhI­II suc­cess sto­ry to tell

8 years ago
R&D

Alzheon files for $80M IPO to take once-failed Alzheimer's drug in­to PhI­II

8 years ago
Financing

Long­time R&D chief Bischof­berg­er leaves Gilead; No­var­tis op­er­a­tions chief heads out; Astel­las taps Bar­ret­to-Ko to run ...

8 years ago
Peer Review

No­var­tis CEO Vas Narasimhan: We can do bet­ter at R&D, but we need FDA’s help; J&J gets $2.1B bid for LifeS­can

8 years ago
News Briefing

FDA OKs Hizen­tra for rare au­toim­mune dis­ease CIDP

8 years ago
Pharma

Pfiz­er per­suades CEO Ian Read to stay on for 1 more year, adding $8M bonus and bump­ing pay pack­age to $28M

8 years ago
People

Lund­beck bags a PhII Parkin­son's drug with $1.1B Prex­ton buy­out deal

8 years ago
Deals

Adap­ti­m­mune shares boost­ed by new signs of suc­cess with TCR cell ther­a­py

8 years ago
R&D

Dems, Re­pub­li­cans split on 340B drug pric­ing pro­gram in Sen­ate hear­ing

8 years ago
Pharma

CRISPR pi­o­neer Feng Zhang co-founds a 'lim­it­less' biotech up­start with big plans for speed­ing new drug de­vel­op­ment

8 years ago
Financing
Startups

Lon­car In­vest­ments launch­es Chi­na bio­phar­ma in­dex; La Jol­la prices $100M pub­lic of­fer­ing

8 years ago
News Briefing
First page Previous page 1042104310441045104610471048 Next page Last page
A service from the Financial Times